close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pheast Therapeutics

News headline image
Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Therapeutics to Host Educational KOL Webinar on Emerging Role of Macrophage Checkpoint Biology for the Treatment of Solid Tumors
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Therapeutics Announces Publication in Clinical Cancer Research Demonstrating Robust Anti-Tumor Activity of PHST001
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Therapeutics Presents Preclinical Data on PHST677, a Novel Bispecific ADC Targeting CDH1 and Nectin-4 at PEGS Boston Summit 2026
From Pheast Therapeutics
Via GlobeNewswire
News headline image
Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026
From Pheast Therapeutics
Via GlobeNewswire
News headline image
Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts
From Pheast Therapeutics
Via GlobeNewswire
News headline image
Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor
From Pheast Therapeutics
Via Business Wire
News headline image
Pheast Appoints Jacopo Leonardi as Chief Executive Officer
From Pheast Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.